Ullén, A., Vulsteke, C., Bedke, J., Rausch, S., Gupta, S., Kang, S., Aragon-Ching, J. B., Vaca, L. B., Paramonov, V., Peer, A., Stus, V., Atduev, V., Nakane, K., Lichfield, J., Meng, C., Huang, D., Ramamurthy, C., Moreno, B. H., Galsky, M. D. (2026). Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.638